Company Profile

Cannasouth Limited is a New Zealand-based medicinal cannabis company. The Company is a vertically integrated biopharmaceutical company dedicated to advanced product development and research. It produces cannabis-based medicines and ingredients using cannabinoid extracts from high-quality, medical-grade cultivars and holds end-to-end GMP licenses for the manufacturing of medicines including dried cannabis flower, CBD oral solutions, and pharmaceutical ingredients. It offers a suite of medicinal cannabis products, raw materials, and laboratory services for export markets, and the local medicinal cannabis markets. It provides a range of imported Cannasouth-branded medicinal cannabis products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, RestoreMe Clinic Limited, Cannasouth Cultivation Limited, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

11/12/24	Cannasouth to Delist from New Zealand Bourse on Dec. 17	MT
31/07/24	Cannasouth Limited announced that it has received NZD 1.22 million in funding	CI
01/07/24	Cannasouth Subsidiaries Execute Deed of Company Arrangement	MT
29/05/24	Cannasouth Sets Watershed Meeting for June 7	MT
15/04/24	Cannasouth Terminates COO	MT
11/04/24	New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	MT
11/04/24	Cannasouth CEO Resigns	MT
28/03/24	Cannasouth Enters Voluntary Administration, CFO Resigns	MT
28/03/24	Cannasouth Extends Trading Halt, Mulls Restructuring Options	MT
26/03/24	Cannasouth Shares Placed on Trading Halt	MT
23/01/24	Cannasouth Limited Reports Revenue Results for the Month of December 2023	CI
21/12/23	Cannasouth Issues NZ$1.1 Million Convertible Bonds	MT
12/12/23	Cannasouth Raises Over NZ$2 Million from Sale of Shares, Bonds	MT

Manager	Title	Age	Since
Pierre Booysen CMP	Compliance Officer	-	-
Tony Clark COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Peng Ho CHM	Chairman	67	26/09/2018
Mark Scapens BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CANNASOUTH LIMITED	+2.08%	-2.00%	-	-	19.01M
LONZA GROUP AG	-0.33%	+1.22%	+2.91%	+7.17%	50.35B
REVOLUTION MEDICINES, INC.	+0.55%	-2.88%	+382.07%	+593.81%	39.32B
IQVIA HOLDINGS INC.	+0.13%	-0.19%	+29.79%	-6.00%	34.69B
BEONE MEDICINES AG	+0.86%	-0.78%	+21.58%	+56.15%	34.08B
CELLTRION, INC.	-1.31%	-3.03%	+2.51%	+25.24%	26.63B
ASCENDIS PHARMA A/S	+0.13%	-0.52%	-	-	16.49B
MEDPACE HOLDINGS, INC.	+1.13%	-1.85%	+67.36%	+120.46%	15.31B
EUROFINS SCIENTIFIC SE	+0.17%	+3.07%	+14.66%	+17.67%	13.8B
ICON PUBLIC LIMITED COMPANY	+1.13%	-0.44%	+12.34%	-31.79%	12.87B
Average	+0.45%	-0.82%	+66.65%	+97.84%	27.06B
Weighted average by Cap.	+0.17%	-0.73%	+81.04%	+122.30%

Cannasouth Limited Stock

Stocks

CBD

NZCBDE0009S6

Biotechnology & Medical Research

Latest news : Cannasouth Limited

Press Releases: Cannasouth Limited

Quotes and Performance

Managers and Directors: Cannasouth Limited

Other Biotechnology & Medical Research

Company Profile